NLRP3 and obesity disorder: In contrast to semaglutide and calorie restriction, only NLRP3 inhibitors significantly lowered cardiovascular inflammatory markers like sVCAM-1 and PCSK9, which indicates potential benefit in cardiovascular risk reduction in individuals with obesity [76].